Third Quarter 2017 Results

Bayer AG News Conference Call

Third quarter of 2017:

Bayer: Sales and earnings increased

  • Covestro deconsolidated

  • Group sales grow by 1.2 percent (Fx & portfolio adj.) to EUR 8,025 million

  • EBITDA before special items up by 4.1 percent to EUR 2,204 million

  • Sales and earnings growth at Pharmaceuticals

  • Consumer Health business weak, as expected

  • Sales gains at Crop Science and Animal Health

  • Net income of EUR 3,881 million including Covestro book profit

  • Core earnings per share at EUR 1.47 (minus 3.9 percent)

  • Group outlook for 2017 confirmed based on change in structure
    » more



Interim Report Q3 2017
Press kit



Follow the coverage in our social media channel:

twitter_38x38_2   Twitter 

   You will find the key statements on » Twitter